Publications by authors named "Michael Wonder"

Claim this Profile
A
Analysis of consumer comments into PBAC decision-making (2014-9).
Emily Tjeuw, Michael J Wonder

Int J Technol Assess Health Care· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of PBAC submissions and outcomes for medicines (2010-2018).
Sean Lybrand, Michael Wonder

Int J Technol Assess Health Care· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of sponsor hearings on health technology assessment decision making.
Melinda Flowers, Sean Lybrand, Michael Wonder

Aust Health Rev· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"Mind the Gap" Revisited.
John R Zalcberg, Michael Wonder

Semin Oncol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subsidised access to new melanoma drugs: in need of further innovation?
Michael Wonder, Rosalie Fisher

N Z Med J· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What impact does 'conventional' economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005-2012).
Michael Wonder, Geoffrey Chin

Expert Rev Pharmacoecon Outcomes Res· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Registration and Reimbursement of New Cancer Medicines in Australia.
Michael Wonder

Value Health Reg Issues· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author reply: exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand.
Colman B Taylor, Michael Wonder

Aust Health Rev· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand.
Colman Taylor, Michael Wonder

Aust Health Rev· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the Quality of the Clinical Evidence in Submissions to the Australian Pharmaceutical Benefits Advisory Committee: Fit for Purpose?
Michael Wonder, Sheryl Dunlop

Value Health· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the therapeutic value of new medicines marketed in Australia.
Michael J Wonder

J Pharm Policy Pract· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What can be gained from increased early-stage interaction between regulators, payers and the pharmaceutical industry?
Michael Wonder

Expert Rev Pharmacoecon Outcomes Res· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is there any evidence that the Trans Pacific Partnership Agreement will threaten access to affordable medicines and health equity in New Zealand?
Michael Wonder, Richard Milne

Health Policy· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early scientific advice obtained simultaneously from regulators and payers: findings from a pilot study in Australia.
Michael Wonder, Martin E Backhouse, Edward Hornby

Value Health· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delays in access to affordable medicines: putting policy into perspective.
Michael Wonder, Geoffrey Chin

Aust Health Rev· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing subsidized access to medicines across payer systems.
Michael Wonder, Richard Milne

Pharmacoeconomics· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient access to new cancer drugs in the United States and Australia.
Michael Wonder

Value Health· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Australian managed entry scheme: a new manageable process for the reimbursement of new medicines?
Michael Wonder, Martin E Backhouse, Sean D Sullivan

Value Health· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to PHARMAC on Access to new medicines in New Zealand compared to Australia.
Richard Milne, Michael Wonder

N Z Med J· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Access to new medicines in New Zealand compared to Australia.
Michael Wonder, Richard Milne

N Z Med J· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study.
Martin E Backhouse, Michael Wonder, Edward Hornby, Anne Kilburg, Michael Drummond

Value Health· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V.
Jack M Mycka, Renato Dellamano, Eugene Mick Kolassa, Michael Wonder, Sabyasachi Ghosh

Value Health· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drugs down under.
Michael J Wonder, Debbie Wyber

Health Aff (Millwood)· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are Australians able to access new medicines on the pharmaceutical benefits scheme in a more or less timely manner? An analysis of pharmaceutical benefits advisory committee recommendations, 1999-2003.
Michael J Wonder, A Munro Neville, Richard Parsons

Value Health· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a predictive population survival model according to the cytogenetic response rate for patients with chronic myeloid leukemia in the chronic phase.
Rudolf J Schrover, Michael A Adena, Richard De Abreu Lourenco, H Miles Prince, John F Seymour, Michael J Wonder

Leuk Lymphoma· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis